Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03292458 · ClinicalTrials.gov registry record · Phase 2

Sodium Oxybate in Spasmodic Dysphonia and Voice Tremor

A Phase 2 study of Spasmodic Dysphonia and Voice Tremor, sponsored by Kristina Simonyan.

Completed
Registry status
Phase 2
Development phase
117
Enrollment target
1
Study location

NCT03292458 is a Phase 2 study of Spasmodic Dysphonia and Voice Tremor that has completed, run by Kristina Simonyan. The registered enrollment target is 117 participants, above the 98-participant average among 7 other Spasmodic Dysphonia trials with a reported enrollment target (19% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03292458, a Phase 2 study of Spasmodic Dysphonia and Voice Tremor, has completed, sponsored by Kristina Simonyan.

COMPLETED
Registry status
Phase 2
Development phase
117 participants
Enrollment target
1
Study location

Study Summary

Using a comprehensive approach of clinico-behavioral testing, neuroimaging and pharmacogenetics, the researchers will examine the clinical effects of sodium oxybate and the matched placebo on voice symptoms in spasmodic dysphonia and voice tremor.

Interventions

  • DRUG Sodium Oxybate

Study Locations (1)

Massachusetts

  • Massachusetts Eye and Ear - Boston

Trial Details

FieldValue
Enrollment Target 117 participants
Start Date 2018-01-22
Est. Completion 2024-10-11
Phase Phase 2

Sponsor

Kristina Simonyan

5 total trials

What the Registry Record Tells You About NCT03292458

The ClinicalTrials.gov registry entry for NCT03292458 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 117 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 98-participant average among 7 other Spasmodic Dysphonia trials with a reported enrollment target (19% higher). The listed sponsor is Kristina Simonyan, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Spasmodic Dysphonia appearing as the primary indexed condition, and to 1 intervention - of which Sodium Oxybate is the first listed.

NCT03292458 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03292458 about?

NCT03292458 is a clinical study titled "Sodium Oxybate in Spasmodic Dysphonia and Voice Tremor". Using a comprehensive approach of clinico-behavioral testing, neuroimaging and pharmacogenetics, the researchers will examine the clinical effects of sodium oxybate and the matched placebo on voice symptoms in spasmodic dysphonia and voice tremor.

What is the current status of trial NCT03292458?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 117 participants. The study started on 2018-01-22. Estimated completion is 2024-10-11.

What conditions does trial NCT03292458 study?

This clinical trial studies the following conditions: Spasmodic Dysphonia, Voice Tremor.

What interventions are being tested in trial NCT03292458?

The interventions under investigation include: Sodium Oxybate (DRUG).

Who is sponsoring clinical trial NCT03292458?

This trial is sponsored by Kristina Simonyan, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03292458 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Spasmodic Dysphonia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.